Arctigenin Inhibits Liver Cancer Tumorigenesis by Inhibiting Gankyrin Expression via C/EBPα and PPARα

Article English OPEN

Ying Sun; Ying Sun; Yu-jun Tan; Yu-jun Tan; Zhan-zhao Lu; Zhan-zhao Lu; Bing-bing Li; Bing-bing Li; Cheng-hong Sun; Cheng-hong Sun; Tao Li; Tao Li; Li-li Zhao; Li-li Zhao; Zhong Liu; Zhong Liu; Zhong Liu; Gui-min Zhang; Gui-min Zhang; Gui-min Zhang; Jing-chun Yao; Jing-chun Yao; Jing-chun Yao; Jie Li; Jie Li;

(2018)

Publisher: Frontiers Media S.A.

Journal: Frontiers in Pharmacology (issn: 1663-9812)

Publisher copyright policies & self-archiving

Related identifiers: doi: 10.3389/fphar.2018.00268/full, doi: 10.3389/fphar.2018.00268
Subject: arctigenin | gankyrin | RM1-950 | Therapeutics. Pharmacology | PPARα | hepatocellular carcinoma | C/EBPα
mesheuropmc: digestive system diseases

Burdock (Arctium lappa) is a popular vegetable in China and Japan that is consumed for its general health benefits. The principal active component of burdock is arctigenin, which shows a range of bioactivities in vivo and in vitro. Here, we investigated the potential an... View more

Metrics

Share - Bookmark

Download from
Frontiers in Pharmacology via DOAJ-Articles (Article, 2018)
Frontiers Media S.A./ Frontiers in Pharmacology
Cite this publication